Experimental cancer combo trial ends early

NCT ID NCT06035744

Terminated Disease control Sponsor: Cullinan Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLN-617 (a fusion protein combining IL-2, LAIR2, HSA, and IL-12) and pembrolizumab (Keytruda)
What this could lead to: If successful, this could point toward a new combination treatment for advanced solid tumors that have stopped responding to standard therapy.
What could go wrong: This is a very early Phase 1 trial, now terminated, so results are limited. The approach is still experimental and may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
MD Anderson

Houston, Texas, 77030, United States
Orlando Health

Orlando, Florida, 32806, United States
USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.